Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Core Transcriptional Regulatory Circuitries in AML

Maxim Pimkin, MD PhD, Juliana Xavier Ferrucio, PhD, Neekesh Vijay Dharia, MD PhD, Taku Harada, Andrew Kossenkov, Selma Elsarrag, Jazmin Ewers, Charles Y Lin, PhD, Kimberly Stegmaier, MD, Stuart H. Orkin, MD

Blood (2019) 134 (Supplement_1): 280.

https://doi.org/10.1182/blood-2019-129297

Published: 2019

Journal Articles

Addiction of B Cell Lymphomas to microRNA-17-92 Is Mediated By a Single Target Gene

Katia Schoeler, Teresa Mittermeier, Andreas Villunger, Klaus Rajewsky, MD, Verena Labi, PhD

Blood (2019) 134 (Supplement_1): 1258.

https://doi.org/10.1182/blood-2019-126483

Published: 2019

Journal Articles

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Julie Devin, PharmD, Tatiana Cañeque, Yea-Lih Lin, PhD, Guillaume Cartron, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Raphael Rodriguez, Jerome Moreaux, PhD

Blood (2019) 134 (Supplement_1): 3960.

https://doi.org/10.1182/blood-2019-129954

Published: 2019

Journal Articles

Myc and the Warburg Effect

Stefano Casola, MD PhD, Gabriele Varano, Laura Perucho, Marianna Ossorio, Federica Zanardi, Martina Sormani, Valentina Petrocelli, Christin Zasada, Stefan Kempa, Klaus Rajewsky, Maurilio Ponzoni, MD, Fabio Facchetti

Blood (2018) 132 (Supplement 1): SCI-12.

https://doi.org/10.1182/blood-2018-99-109471

Published: 2018

Journal Articles

Low Enrollment of Adult Patients in Clinical Trials: Is Communication Still a Problem?

Alina Basnet, MBBS, Cheryl A Roe, MS, Stephen Graziano, MD, Damare Sherri, MSN, Maria Serrano, BA

Blood (2017) 130 (Supplement 1): 3399.

https://doi.org/10.1182/blood.V130.Suppl_1.3399.3399

Published: 2017

Journal Articles

Myeloma Cell Addiction to the Transcription Factor TCF11

Valentina Caputo, PhD, Katerina Goudevenou, PhD, Nikolaos Trasanidis, BSc, MSc, Kyriaki Petevi, MD, Xiaolin Xiao, PhD, Kanagaraju Ponnusamy, PhD, Deena Iskander, MD, David Pitcher, PhD, Antonia Rotolo, MD, Holger W. Auner, MD PhD, Aristeidis Chaidos, MD PhD, Anastasios Karadimitris, PhD

Blood (2017) 130 (Supplement 1): 1194.

https://doi.org/10.1182/blood.V130.Suppl_1.1194.1194

Published: 2017

Journal Articles

Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors

Yinon Ben-Neriah, MD PhD, Avanthika Venkatachalam, MSc, Avner Fink, PhD, Eric Hung, MSc, Joseph Vacca, PhD, Frank Mercurio, PhD, Moshe Oren, PhD, Eli Pikarsky, MDPhD, Irit Snir-Alkalay, PhD, Waleed Minzel, MSc

Blood (2017) 130 (Supplement 1): 812.

https://doi.org/10.1182/blood.V130.Suppl_1.812.812

Published: 2017

Journal Articles

Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia

Marco De Dominici, MS, Angela Rachele Soliera, PhD, Patrizia Porazzi, PhD, Samanta A. Mariani, PhD, Sankar Addya, PhD, Luke F. Peterson, PhD, Orietta Spinelli, PhD, Alessandro Rambaldi, MD Prof, Giovanni Martinelli, MD, Ilaria Iacobucci, PhD, Anna Ferrari, PhD, Bruno Calabretta, MD PhD

Blood (2017) 130 (Supplement 1): 2490.

https://doi.org/10.1182/blood.V130.Suppl_1.2490.2490

Published: 2017

Journal Articles

Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma

Sho Ikeda, MD, Akihiro Kitadate, MD, Fumito Abe, MD PhD, Naoto Takahashi, Hiroyuki Tagawa, MD PhD

Blood (2017) 130 (Supplement 1): 3061.

https://doi.org/10.1182/blood.V130.Suppl_1.3061.3061

Published: 2017

Journal Articles

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Kathrin Stangelberger, MSc, Muller Joséphine, Marla Weetall, PhD, Art Branstrom, PhD, Niklas Zojer, MD, Jo Caers, MD, Heinz Ludwig, MD

Blood (2017) 130 (Supplement 1): 1804.

https://doi.org/10.1182/blood.V130.Suppl_1.1804.1804

Published: 2017

Journal Articles

FOXtrotting with PUMILIOs

Arefeh Rouhi, Florian Kuchenbauer

Blood (2017) 129 (18): 2459–2460.

https://doi.org/10.1182/blood-2017-03-771469

Published: 2017

Journal Articles

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

Meenu Kesarwani, PhD, Zachary Kincaid, BS, Ahmed Ramadan Gomma, PhD, Erika Huber, Sara Rohrabaugh, PhD, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 3056.

https://doi.org/10.1182/blood.V128.22.3056.3056

Published: 2016

Journal Articles

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Mariateresa Fulciniti, PhD, Joaquin Martinez Lopez, MD PhD, William Senapedis, PhD, Stefania Oliva, MD, Raphaël Szalat, MD, Mehmet K. Samur, PhD, Rao H Prabhala, PhD, Kenneth C. Anderson, MD, Nikhil C Munshi, MD

Blood (2016) 128 (22): 3302.

https://doi.org/10.1182/blood.V128.22.3302.3302

Published: 2016

Journal Articles

SET8 Is a Potential Therapeutic Target in MM

Herviou Laurie, Fanny Izard, Elke De Bruyne, PhD, Eva Desmedt, Anqi Ma, PhD, Jian Jin, PhD, Karin Vanderkerken, PhD, Eric Julien, Jerome Moreaux, PhD

Blood (2016) 128 (22): 4435.

https://doi.org/10.1182/blood.V128.22.4435.4435

Published: 2016

Journal Articles

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia

Blood (2016) 128 (22): 1533.

https://doi.org/10.1182/blood.V128.22.1533.1533

Published: 2016

Journal Articles

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Sara Rohrabaugh, PhD, Meenu Kesarwani, PhD, Zachary Kincaid, BS, Erika Huber, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 632.

https://doi.org/10.1182/blood.V128.22.632.632

Published: 2016

Journal Articles

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target

Blood (2016) 128 (5): 667–679.

https://doi.org/10.1182/blood-2016-01-690743

Published: 2016

Includes: Supplemental data

Journal Articles

Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Nassera Abermil, MS, PharmD, Frederick Lansigan, MD, William Kinlaw, MD, Ron Gartenhaus, MD, Graham Jones, PhD DSc, Lynn Hlatky, PhD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 1284.

https://doi.org/10.1182/blood.V126.23.1284.1284

Published: 2015

Journal Articles

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Annie Guerin, MSc, Saurabh Ray, PhD, Genevieve Gauthier, MSc, Ling-I Hsu, PhD, Maryia Zhdanava, Eric Wu, PhD

Blood (2015) 126 (23): 3313.

https://doi.org/10.1182/blood.V126.23.3313.3313

Published: 2015

NARROW

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Core Transcriptional Regulatory Circuitries in AML

Addiction of B Cell Lymphomas to microRNA-17-92 Is Mediated By a Single Target Gene

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Myc and the Warburg Effect

Low Enrollment of Adult Patients in Clinical Trials: Is Communication Still a Problem?

Myeloma Cell Addiction to the Transcription Factor TCF11

Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors

Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia

Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma

Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma

FOXtrotting with PUMILIOs

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

SET8 Is a Potential Therapeutic Target in MM

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target

Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only